Tsukiyama I - Search Results

1

[A smear method for measuring anti-cancer drugs residues in hospitals].

Takano T, Suzuki S, Tsukiyama I, Saito H. Takano T, et al. Among authors: tsukiyama i. Sangyo Eiseigaku Zasshi. 2015;57(6):275-85. doi: 10.1539/sangyoeisei.B15004. Epub 2015 Aug 12. Sangyo Eiseigaku Zasshi. 2015. PMID: 26268549 Free article. Japanese.

2

[A case of Ifosfamide-induced dysuria which could be avoided by changing the regimen of mesna].

Yamamoto Y, Tsukiyama I, Nii S, Harada R, Watanabe K, Yabushita H, Wakatsuki A, Saito H, Hasegawa T. Yamamoto Y, et al. Among authors: tsukiyama i. Gan To Kagaku Ryoho. 2013 Mar;40(3):413-5. Gan To Kagaku Ryoho. 2013. PMID: 23507611 Japanese.

3

Evaluation of safety in clinical use of generic paclitaxel [NK] for injection.

Tsukiyama I, Hotta K, Takeuchi M, Onishi M, Toyama Y, Saito H, Sai Y, Miyamoto K, Hasegawa T. Tsukiyama I, et al. Gan To Kagaku Ryoho. 2012 Apr;39(4):613-7. Gan To Kagaku Ryoho. 2012. PMID: 22504687

4

De-alcoholization of paclitaxel injection for clinical application.

Tsukiyama I, Takeuchi M, Abe F, Kisi T, Saito H, Obayashi Y, Watanabe K, Wakatsuki A, Miyamoto K, Hasegawa T. Tsukiyama I, et al. Anticancer Res. 2011 Dec;31(12):4339-46. Anticancer Res. 2011. PMID: 22199299

5

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.

Tsukiyama I, Ejiri M, Yamamoto Y, Nakao H, Yoneda M, Matsuura K, Arakawa I, Saito H, Inoue T. Tsukiyama I, et al. J Gastrointest Cancer. 2017 Dec;48(4):326-332. doi: 10.1007/s12029-016-9885-6. J Gastrointest Cancer. 2017. PMID: 27785685 Free PMC article.

6

Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.

Kato A, Ueyama J, Abe F, Hotta K, Tsukiyama I, Oshima T, Kondo F, Saito H, Hasegawa T. Kato A, et al. Among authors: tsukiyama i. Anticancer Res. 2011 Sep;31(9):2915-22. Anticancer Res. 2011. PMID: 21868538

7

Lack of Contribution of Multidrug Resistance-associated Protein and Organic Anion-transporting Polypeptide to Pharmacokinetics of Regorafenib, a Novel Multi-Kinase Inhibitor, in Rats.

Hotta K, Ueyama J, Tatsumi Y, Tsukiyama I, Sugiura Y, Saito H, Matsuura K, Hasegawa T. Hotta K, et al. Among authors: tsukiyama i. Anticancer Res. 2015 Sep;35(9):4681-9. Anticancer Res. 2015. PMID: 26254357

8

Cost-effectiveness of aprepitant in Japanese patients treated with cisplatin-containing highly emetogenic chemotherapy.

Tsukiyama I, Hasegawa S, Ikeda Y, Takeuchi M, Tsukiyama S, Kurose Y, Ejiri M, Sakuma M, Saito H, Arakawa I, Inoue T, Yamaguchi E, Kubo A. Tsukiyama I, et al. Cancer Sci. 2018 Sep;109(9):2881-2888. doi: 10.1111/cas.13736. Epub 2018 Aug 3. Cancer Sci. 2018. PMID: 29999572 Free PMC article. Clinical Trial.

9

Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.

Toyama Y, Ueyama J, Nomura H, Tsukiyama I, Saito H, Hisada T, Matsuura K, Hasegawa T. Toyama Y, et al. Among authors: tsukiyama i. Anticancer Res. 2014 May;34(5):2283-9. Anticancer Res. 2014. PMID: 24778032

10

Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes.

Arakawa-Todo M, Yoshizawa T, Zennami K, Nishikawa G, Kato Y, Kobayashi I, Kajikawa K, Yamada Y, Matsuura K, Tsukiyama I, Saito H, Hasegawa T, Nakamura K, Sumitomo M. Arakawa-Todo M, et al. Among authors: tsukiyama i. Anticancer Res. 2013 Nov;33(11):5043-50. Anticancer Res. 2013. PMID: 24222148

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

102 results

Search Page

Filters